Continuation versus Interruption of Oral Anticoagulation during TAVI

In a randomized trial involving patients undergoing TAVI, periprocedural continuation of oral anticoagulants was not noninferior to interruption of these drugs with respect to adverse events at 30 days.

​   The New England Journal of Medicine: Search Results in Cardiology